TFF Pharmaceuticals and Catalent today announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics.

Catalent today announced that it plans to expand its Waigaoqiao Free Trade Zone (FTZ) facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies.

Catalent today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2022 in both the United States and the United Kingdom.

Catalent today announced that it has completed a $10 million expansion at its Malvern, Pennsylvania, and Dartford, U.K., facilities, to provide advanced containment capabilities for the micronization of highly potent drug compounds.

Catalent today announced the launch of its new Xpress Pharmaceutics™ service, designed to accelerate the development of oral drugs through Phase 1 clinical studies.

Catalent today announced that it has increased cold chain packaging capabilities at its Philadelphia facility to support increased demand for the distribution of biologic drugs, and advanced cell and gene therapies.

Catalent today announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022.

NurOwn is BrainStorm’s autologous cellular therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (PMS) and other neurodegenerative diseases.

The selection follows a seven-month formulation development program conducted by Catalent, in which the API was screened for ideal formulation conditions, with a number of potential excipients, to come up with a drug product that suits ProtoKinetix’s needs.